Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flow from operating activities:
Net loss	$ (22,013)	$ (64,017)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	2,156	2,363
Non cash lease expense	45	(19)
Provision for doubtful accounts	201	611
Provision for inventory obsolescence	(45)
Change in fair value of warrant liabilities	8,875	(1,735)
Goodwill impairment	0	29,633
Stock-based compensation expense	2,966	3,988
Change in fair value of contingent consideration		(18,932)
Acquired in-process research and development		3,000
Issuance of common stock for stem-cells to be used in research and development		1,000
Issuance of common stock to Palantir as consideration for settlement agreement	50
Issuance of common stock relating to Yorkville for debt extension and SEPA commitment fee	317
Change in fair value of contingent stock consideration		(110)
Loss on extinguishment of debt	3,908	0
Change in fair value of debt	(81)	1,280
Non cash interest expense	1,148
Other, net	181	272
Changes in assets and liabilities:
Accounts receivable	(3,924)	791
Inventory	3,181	(1,813)
Prepaid expenses and other assets	294	1,463
Accounts payable	(1,172)	2,730
Accrued expenses and other liabilities	1,171	729
Accrued R&D software	(1,800)	23,675
Lease liabilities - operating	88	64
Deferred revenue	51	32
Net cash used in operating activities	(4,403)	(14,995)
Cash flow from investing activities:
Capital expenditures	(39)	(209)
Purchase of acquired in-process research and development		(3,000)
Net cash used in investing activities	(39)	(3,209)
Cash flow from financing activities:
Proceeds from warrants and short-term debt - related parties	15,000	4,994
Proceeds from the exercise of stock options		300
Repayments of short-term debt - unaffiliated	(17,374)	(1,618)
Proceeds from issuance of short-term debt - unaffiliated	2,993
Payment of SEPA commitment fee	(25)
Repayments of short-term debt - related parties	(10)
Proceeds from PIPE Offering, net of offering costs	6,000	9,000
Proceeds from the sale of common stock in ATM offering		136
Tax withholding on vesting of restricted stock units	(357)	(53)
Net cash provided by financing activities	6,227	12,759
Net increase (decrease) in cash, cash equivalents and restricted cash	1,785	(5,445)
Cash, cash equivalents and restricted cash at beginning of period	10,163	28,802
Cash, cash equivalents and restricted cash at end of period	11,948	23,357
Supplemental Cash Flow Information [Abstract]
Cash paid for interest		251
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	(11)	(697)
Modification of C.V. Starr warrants in connection with forbearance	51
Issuance of RWI warrants in connection with forbearance	$ 1,223
Issuance of warrants on senior secured bridge loan		274
PIPE related offering costs included in accrued expenses		(69)
Common stock issued for short-term debt conversion		$ 3,510